Bendamustine
Treanda · Alkylator
Tumor lysis-mediated AKI is the principal risk; TMA is rare.
PRETMALYTE
ModerateOpen →
Purine analog
Nelarabine
Arranon · Nelar
A T-cell-selective purine analog whose rapid leukemic kill can trigger tumor lysis and prerenal AKI.
MildPurine nucleoside analog · approved 2005
Relapsed/refractory T-cell acute lymphoblastic leukemiaT-cell lymphoblastic lymphoma
Signature kidney injury
Prerenal / Hemodynamic AKI
Tumor lysis syndrome with attendant AKI is a labeled risk when bulky T-ALL responds rapidly; drug-specific renal incidence is not well quantified (case-level). The dose-limiting and most feared toxicity is neurologic, not renal.
Source: Izzedine & Perazella, Kidney Int Rep 2017 (review)
Mechanism of kidney injury
Rapid lysis of T lymphoblasts releases uric acid, phosphate and potassium; intratubular crystal/cast deposition combined with volume depletion drives prerenal and ischemic AKI (tumor lysis nephropathy). Direct tubular nephrotoxicity from nelarabine itself is not a prominent feature.
Clinical presentation
Hyperuricemia, hyperphosphatemia, hyperkalemia, hypocalcemia and a rising creatinine after treatment; the dominant non-renal toxicity is severe neurotoxicity (somnolence, peripheral neuropathy, seizures), which can confound the clinical picture.
Onset
Early after treatment initiation (days).
Reversibility
Reversible
Anticancer mechanism
Water-soluble prodrug of ara-G (9-beta-D-arabinofuranosylguanine), demethylated by adenosine deaminase, that accumulates preferentially in T lymphoblasts where it is phosphorylated to ara-GTP, incorporated into DNA and halts DNA synthesis, causing apoptosis. Used for relapsed or refractory T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma, and now incorporated into frontline pediatric T-ALL therapy.
Management
Treat tumor lysis with hydration, urate-lowering therapy and electrolyte correction; supportive care and renal replacement therapy for severe AKI. Discontinue for grade >=2 neurologic events (which are not reversed by drug-level reduction). Adequate hydration also limits intratubular crystal deposition.
Risk factors
- High tumor burden T-ALL / lymphoblastic lymphoma
- Baseline hyperuricemia or renal impairment
- Volume depletion
Prevention
- IV hydration during cytoreduction
- Allopurinol or rasburicase prophylaxis in at-risk patients
- Monitor uric acid, phosphate, potassium and creatinine
Note · Renal risk is essentially tumor-lysis related rather than direct tubular toxicity; evidence is conservative/case-level. The black-box warning is for neurotoxicity, not nephrotoxicity.
Clinical depth
Renal dose adjustment
No specific renal dose adjustment is defined in the label, but exposure is higher and clearance lower in renal impairment, so the FDA label advises monitoring patients with CrCl < 50 mL/min closely for increased toxicity. Ara-G is renally cleared.
Dialyzability & ESKD dosing
Not formally established; ara-G is a small renally excreted molecule with theoretical dialytic removal, but no validated supplemental dosing exists and HD is used only to manage AKI complications.
Differential diagnosis
Distinguish tumor lysis nephropathy (urate/phosphate surge) from prerenal azotemia and from leukemic infiltration of the kidney. Note that altered mental status in these patients may reflect nelarabine neurotoxicity rather than uremia/metabolic encephalopathy.
Monitoring
- Uric acid, phosphate, potassium, calcium and creatinine at initiation and during early cycles
- Frequent neurologic examinations (the dose-limiting toxicity)
- CBC for myelosuppression
Key trials & series
- Children's Oncology Group AALL0434 phase III trial adding nelarabine to frontline T-ALL therapy (Dunsmore, J Clin Oncol 2020)
- Phase II relapsed/refractory T-ALL studies underpinning approval
Clinical pearls
- Nelarabine's signature toxicity is neurologic; the renal risk is the tumor lysis that accompanies rapid T-ALL kill.
- Hydration plus urate-lowering therapy at the start of a responding course is the key renal protection.
- A creatinine rise with new confusion should prompt separate evaluation of TLS and CNS toxicity.
Where it strikes
Nephron segments
Vasculature / Endothelium
Glomerular & peritubular capillaries
Tubular Lumen
The urine flow path
Injury signatures
Prerenal / Hemodynamic AKIElectrolyte Wasting
Beyond the kidney
Class-level context for the major non-renal toxicities of purine analogs.
Gastrointestinal
Diarrhea, colitis, mucositis, perforation
- Mucositis and diarrhea
Hepatic / Liver
Transaminitis, hepatitis, VOD/SOS
- Transaminitis (methotrexate)
Hematologic
Cytopenias, thrombosis, TMA
- Myelosuppression
Pulmonary
Pneumonitis, ILD, effusions, hypertension
- Methotrexate / gemcitabine pneumonitis
Evidence
6 peer-reviewed references. Citation metadata via PubMed / NLM.
LandmarkChildren's Oncology Group AALL0434: A Phase III Randomized Clinical Trial Testing Nelarabine in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia.Dunsmore KP et al. · J Clin Oncol 2020 · PMID 32813610Definitive randomized trial establishing nelarabine in frontline T-ALL with a full safety profile.PMIDAnticancer Drug-Induced Acute Kidney Injury.Izzedine H et al. · Kidney Int Rep 2017 · PMID 29318217Onco-nephrology review of tumor-lysis and prerenal mechanisms relevant to nucleoside analogs.PMID[Tumor lysis syndrome].Downey AI et al. · Medicina (B Aires) 2019 · PMID 31829957General review of chemotherapy-triggered tumor lysis syndrome and its renal consequences.PMIDRecommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus.Cairo MS et al. · Br J Haematol 2010 · PMID 20331465Risk-stratified prophylaxis framework for the tumor-lysis AKI risk in bulky T-ALL.PMIDNew drug toxicities in the onco-nephrology world.Perazella MA et al. · Kidney Int 2015 · PMID 25671763Onco-nephrology review covering newer antileukemic agents.PMIDOnconephrology: The intersections between the kidney and cancer.Rosner MH et al. · CA Cancer J Clin 2020 · PMID 32853404Comprehensive onconephrology review of tumor lysis nephropathy management.
Related agents
Other agents sharing the same signature kidney injury.